أعرض في EDS

Time to embrace access programmes for medicines: lessons from the South African flucytosine access programme

التفاصيل البيبلوغرافية
العنوان: Time to embrace access programmes for medicines: lessons from the South African flucytosine access programme
المؤلفون: Nelesh P. Govender, Carol Ruffell, Angela Loyse, Laura Trivino Duran, Olawale Ajose, John Black, Jeremy Nel, Gilles van Cutsem, Richard A. Murphy, Colin N. Menezes, Amir Shroufi, Mahomed-Yunus S. Moosa, Thomas S. Harrison, Douglas Wilson, Halima Dawood, Graeme Meintjes
المصدر: International Journal of Infectious Diseases, Vol 95, Iss, Pp 459-461 (2020)
بيانات النشر: Elsevier BV, 2020.
سنة النشر: 2020
مصطلحات موضوعية: 0301 basic medicine, Microbiology (medical), Economic growth, medicine.medical_specialty, Antifungal Agents, Product market, Cryptococcal, 030106 microbiology, Flucytosine, Meningitis, Cryptococcal, Health Services Accessibility, World health, lcsh:Infectious and parasitic diseases, South Africa, 03 medical and health sciences, 0302 clinical medicine, Acquired immunodeficiency syndrome (AIDS), AIDS mortality, advanced HIV disease, medicine, Humans, lcsh:RC109-216, 030212 general & internal medicine, Market failure, Access programme, business.industry, Public health, Public sector, HIV, General Medicine, medicine.disease, 5FC, Access, AIDS, Ahd, Infectious Diseases, Cryptococcal meningitis, business, medicine.drug
الوصف: Background Cryptococcal meningitis (CM) is estimated to cause 181 000 deaths annually, with the majority occurring in Sub-Saharan Africa. Flucytosine is recommended by the World Health Organization as part of the treatment for CM. Widespread use of flucytosine could reduce mortality in hospital by as much as 40% compared to the standard of care, yet due to market failure, quality-assured flucytosine remains unregistered and largely inaccessible throughout Africa. Methods The recently established South African flucytosine clinical access programme is an attempt to address the market failure that led to a lack of public sector access to flucytosine for CM, by making the medicine freely available to tertiary hospitals in South Africa. Results Between November 2018 and September 2019, 327 CM patients received flucytosine through this programme, with efforts to support sustainable national scale-up presently ongoing. We describe why this programme was needed, its catalytic potential, what is still required to ensure widespread access to flucytosine, and observations from this experience that may have wider relevance. Conclusions The South African flucytosine access programme illustrates how access programmes may be one part of the solution to addressing the vicious cycle of perceived low demand, limiting manufacturer interest in specific product markets.
وصف الملف: application/pdf
تدمد: 1201-9712
1878-3511
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4b6d9906c1a34a31b5c95f964daff6b
https://doi.org/10.1016/j.ijid.2020.02.057
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....c4b6d9906c1a34a31b5c95f964daff6b
قاعدة البيانات: OpenAIRE
الوصف
تدمد:12019712
18783511